Institution
Wayne State University
Education•Detroit, Michigan, United States•
About: Wayne State University is a education organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 42801 authors who have published 82738 publications receiving 3083713 citations. The organization is also known as: WSU & Wayne University.
Topics: Population, Cancer, Poison control, Pregnancy, Medicine
Papers published on a yearly basis
Papers
More filters
••
University of Texas Health Science Center at Houston1, University of Toronto2, Stony Brook University3, University of New Mexico4, University of Maryland, Baltimore5, Icahn School of Medicine at Mount Sinai6, Maimonides Medical Center7, University of British Columbia8, Université de Montréal9, University of Ottawa10, University of Paris11, Queen's University12, Allegheny General Hospital13, Henry Ford Health System14, University of Pennsylvania15, Indiana University – Purdue University Indianapolis16, Mayo Clinic17, Drexel University18, Shepherd Center19, Ohio State University20, Oregon Health & Science University21, State University of New York Upstate Medical University22, Roswell Park Cancer Institute23, University of California, Davis24, University of California, Irvine25, University of California, Los Angeles26, University of California, San Diego27, University of California, San Francisco28, University of Chicago29, University of Alabama at Birmingham30, University of Kansas31, Rutgers University32, University of Miami33, University of Pittsburgh34, University of Rochester35, University of Southern California36, University of South Florida37, University of Texas Southwestern Medical Center38, University of Washington39, University of Wisconsin-Madison40, University of Utah41, Vanderbilt University42, Wake Forest University43, Washington University in St. Louis44, Wayne State University45, Yale University46, McGill University47, Foothills Medical Centre48, National Institutes of Health49
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
Abstract: Objective
To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis.
Methods
A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3-year, double-blind trial. The primary end point was an intention-to-treat analysis of time to 1- (entry expanded disability status scale, 3.0–5.0) or 0.5-point expanded disability status scale change (entry expanded disability status scale, 5.5–6.5) sustained for 3 months. The trial was stopped after an interim analysis by an independent data safety monitoring board indicated no discernible treatment effect on the primary outcome. Intention-to-treat analyses of disability and magnetic resonance imaging end points were performed.
Results
There was a nonsignificant delay in time to sustained accumulated disability in GA- versus PBO-treated patients (hazard ratio, 0.87 [95% confidence interval, 0.71–1.07]; p = 0.1753), with significant decreases in enhancing lesions in year 1 and smaller increases in T2 lesion volumes in years 2 and 3 versus PBO. Post hoc analysis showed that survival curves for GA-treated male patients diverged early from PBO-treated male subjects (hazard ratio, 0.71 [95% confidence interval, 0.53–0.95]; p = 0.0193).
Interpretation
The trial failed to demonstrate a treatment effect of GA on primary progressive multiple sclerosis. Both the unanticipated low event rate and premature discontinuation of study medication decreased the power to detect a treatment effect. Post hoc analysis suggests GA may have slowed clinical progression in male patients who showed more rapid progression when untreated. Ann Neurol 2007;61:14–24
406 citations
••
TL;DR: It is shown that genetic effects on the immune response are strongly enriched for recent, population-specific signatures of adaptation, including for traits that are key to controlling infection.
405 citations
••
TL;DR: Northern (RNA) and Southern hybridization studies showed that increased transcription, and not gene amplification, of norA1199 is the basis for fluoroquinolone resistance in SA-1199B.
Abstract: Transport processes are used by all organisms to obtain essential nutrients and to expel wastes and other potentially harmful substances from cells. Such processes are important means by which resistance to selected antimicrobial agents in bacteria is achieved. The recently described Staphylococcus aureus norA gene encodes a membrane-associated protein that mediates active efflux of fluoroquinolones from cells. SA-1199B is a fluoroquinolone-resistant strain of S. aureus from which we cloned an allele of norA (norA1199). Similar to that of norA, the protein product of norA1199 preferentially mediates efflux of hydrophilic fluoroquinolones in both S. aureus and an Escherichia coli host, a process driven by the proton motive force. Determination of the nucleotide sequence of norA1199 revealed an encoded 388-amino-acid hydrophobic polypeptide 95% homologous with the norA-encoded protein. Significant homology with other proteins involved in transport processes also exists, but especially with tetracycline efflux proteins and with the Bacillus subtilis Bmr protein that mediates active efflux of structurally unrelated compounds, including fluoroquinolones. In S. aureus, the norA1199-encoded protein also appears to function as a multidrug efflux transporter. Southern hybridization studies indicated that norA1199 (or an allele of it) is a naturally occurring S. aureus gene and that related sequences are present in the S. epidermidis genome. The nucleotide sequence of the wild-type allele of norA1199, cloned from the fluoroquinolone-susceptible parent strain of SA-1199B, did not differ from that of norA1199 throughout the coding region. Northern (RNA) and Southern hybridization studies showed that increased transcription, and not gene amplification, of norA1199 is the basis for fluoroquinolone resistance in SA-1199B.
405 citations
••
TL;DR: Mexican American and African American individuals meeting 12-month major depression criteria consistently and significantly had lower odds for any depression therapy and guideline-concordant therapies despite depression severity ratings not significantly differing between ethnic/racial groups.
Abstract: Objective To determine the prevalence and adequacy of depression care among different ethnic and racial groups in the United States. Design Collaborative Psychiatric Epidemiology Surveys (CPES) data were analyzed to calculate nationally representative estimates of depression care. Setting The 48 coterminous United States. Participants Household residents 18 years and older (N = 15 762) participated in the study. Main Outcome Measures Past-year depression pharmacotherapy and psychotherapy using American Psychiatric Association guideline-concordant therapies. Depression severity was assessed with the Quick Inventory of Depressive Symptomatology Self-Report. Primary predictors were major ethnic/racial groups (Mexican American, Puerto Rican, Caribbean black, African American, and non-Latino white) and World Mental Health Composite International Diagnostic Interview criteria for 12-month major depressive episode. Results Mexican American and African American individuals meeting 12-month major depression criteria consistently and significantly had lower odds for any depression therapy and guideline-concordant therapies despite depression severity ratings not significantly differing between ethnic/racial groups. All groups reported higher use of any past-year psychotherapy and guideline-concordant psychotherapy compared with pharmacotherapy; however, Caribbean black and African American individuals reported the highest proportions of this use. Conclusions Few Americans with recent major depression have used depression therapies and guideline-concordant therapies; however, the lowest rates of use were found among Mexican American and African American individuals. Ethnic/racial differences were found despite comparable depression care need. More Americans with recent major depression used psychotherapy over pharmacotherapy, and these differences were most pronounced among Mexican American and African American individuals. This report underscores the importance of disaggregating ethnic/racial groups and depression therapies in understanding and directing efforts to improve depression care in the United States.
404 citations
••
TL;DR: This work constructs application-oblivious models for the cost prediction by using learned knowledge about the workloads at the hypervisor (also called VMM) level and evaluates the models using five representative workloads on a Xen virtualized environment.
Abstract: Live migration of virtual machine (VM) provides a significant benefit for virtual server mobility without disrupting service. It is widely used for system management in virtualized data centers. However, migration costs may vary significantly for different workloads due to the variety of VM configurations and workload characteristics. To take into account the migration overhead in migration decision-making, we investigate design methodologies to quantitatively predict the migration performance and energy consumption. We thoroughly analyze the key parameters that affect the migration cost from theory to practice. We construct application-oblivious models for the cost prediction by using learned knowledge about the workloads at the hypervisor (also called VMM) level. This should be the first kind of work to estimate VM live migration cost in terms of both performance and energy in a quantitative approach. We evaluate the models using five representative workloads on a Xen virtualized environment. Experimental results show that the refined model yields higher than 90% prediction accuracy in comparison with measured cost. Model-guided decisions can significantly reduce the migration cost by more than 72.9% at an energy saving of 73.6%.
404 citations
Authors
Showing all 43073 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Eugene Braunwald | 230 | 1711 | 264576 |
Rakesh K. Jain | 200 | 1467 | 177727 |
Anil K. Jain | 183 | 1016 | 192151 |
Richard A. Gibbs | 172 | 889 | 249708 |
Bradley Cox | 169 | 2150 | 156200 |
Jun Wang | 166 | 1093 | 141621 |
David Altshuler | 162 | 345 | 201782 |
Elliott M. Antman | 161 | 716 | 179462 |
Jovan Milosevic | 152 | 1433 | 106802 |
Roberto Romero | 151 | 1516 | 108321 |
Kypros H. Nicolaides | 147 | 1302 | 87091 |
John F. Hartwig | 145 | 714 | 66472 |
Charles Maguire | 142 | 1197 | 95026 |
Mingshui Chen | 141 | 1543 | 125369 |